Unusual presentation of serum markers for suspected Pneumocystis jiroveci pneumonia in a patient with diffuse large B-cell lymphoma  by Uchiyama, Michihiro & Ikeda, Takashi
International Journal of Infectious Diseases 14 (2010) e267–e268Letter to the Editor
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journa l homepage: www.e lsev ier .com/ locate / i j idUnusual presentation of serum markers for suspected Pneu-
mocystis jirovecipneumonia in a patientwith diffuse large B-cell
lymphoma
Pneumocystis jiroveci pneumonia (PCP) is an important cause of
morbidity and mortality in immunocompromised patients.1
Diagnosis of PCP is based on direct microscopic examination to
identify Pneumocystis from induced sputum or bronchoalveolar
lavage (BAL) ﬂuid. PCP patients without HIV infection have a lower
burden of Pneumocystis than those with HIV infection, leading to
difﬁculties in detecting the organism.1,2 The polymerase chain
reaction (PCR) assay offers higher sensitivity and speciﬁcity than
conventional stains for the diagnosis of PCP, and several reports
have demonstrated high success rates for the diagnosis of PCP in
both HIV-positive and -negative patients.3–6
We describe herein an interesting case, strongly suspected as
PCP, with unusual presentation of serum markers in an HIV-
negative patient with diffuse large B-cell lymphoma. Radiological
ﬁndings and PCR positivity for Pneumocystis in BAL ﬂuid suggested
PCP in this case.
A 72-year-old woman had been treated with 21-day interval
rituximab–cyclophosphamide–doxorubicin–vincristine–predni-
solone (R-CHOP) therapy for diffuse large B-cell lymphoma. On day
12 after starting the second cycle of R-CHOP therapy, she
developed a febrile illness with general malaise and fatigability.
On admission, she was febrile with a body temperature of 38.6 8C,
but physical examination revealed normal results including on
lung examination. Laboratory examination revealed an extremely
low white blood cell (WBC) count (0.67  109/l), and serum C-
reactive protein (CRP) levels were elevated (2.20 mg/dl). A broad-
spectrum antibiotic agent (meropenem), an antifungal agent
(itraconazole), and granulocyte colony-stimulating factor (leno-
grastim) were thus administered for febrile neutropenia until a
neutrophil count consistently above 0.5  109/l was achieved.
Progressive exertional dyspnea developed on day 16. Arterial
blood gas values while breathing room air were as follows: PaO2
58.2 Torr, PaCO2 32.3 Torr, pH 7.484, and an abnormal alveolar–
arterial oxygen gradient (51.4 Torr). Chest radiography showedFigure 1. (a) Postero-anterior chest radiograph of the tho
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Computed tomography (CT) of the chest revealed sparsely
distributed ground-glass opaciﬁcation throughout bilateral lung
ﬁelds (Figure 1).
Laboratory ﬁndings on day 16 are summarized in Table 1. The
WBC countwas 6.64  109/l with 3% lymphocytes (CD4-positive T-
lymphocytes, 0.18  109/l). Elevations were noted in serum CRP,
but lactate dehydrogenase (LDH), mucin KL-6, and b-D-glucan
remained within normal limits. Testing for HIV yielded negative
results, and no other viral infections were conﬁrmed on serological
tests. BAL ﬂuid showed P. jiroveci according to a PCR assay, with
32% macrophages, 52% lymphocytes, and 10% neutrophils. No
other infectious agents were identiﬁed from BAL ﬂuid, including
cytomegalovirus, human herpesvirus-6, Candida, and Aspergillus.
Galactomannan testing in BAL ﬂuid also yielded negative results.
Although results for serological markers such as serum CRP, LDH,
KL-6, and b-D-glucan were all negative and BAL ﬂuid was negative
on Grocott staining, PCP was ﬁnally diagnosed based on
radiological ﬁndings and PCR positivity for Pneumocystis in BAL
ﬂuid.
Therapy was initiated with nine tablets per day of trimetho-
prim–sulfamethoxazole (TMP–SMX; 80 mg of TMP and 400 mg of
SMX per tablet) and 2 mg/kg/day methylprednisolone (mPSL),
leading to gradual improvements in both radiological ﬁndings and
hypoxemia. High-dose TMP–SMX was stopped after 2 weeks of
administration, and corticosteroid was tapered every 5 days as
follows: 80 mg/day mPSL; 40 mg/day mPSL; 20 mg/day predniso-
lone (PSL); and 5 mg/day PSL. Pharmacotherapy against Pneumo-
cystis infection has continued at a dosage of one tablet per day.
The diagnosis of PCP, particularly in the early stages, is
cumbersome. As PCP patients without HIV infection have a lower
burden of Pneumocystis, direct microscopic detection of Pneu-
mocystis from clinical specimens is difﬁcult.1,2 Recent reports have
demonstrated that serum b-D-glucan can represent a valuable
noninvasive serologic marker to help diagnose and manage PCP.7,8
However, not only b-D-glucan but also LDH and KL-6 were within
normal limits in this case. PCR has been used successfully to detect
Pneumocystis and a positive result correlates with clinicalrax. (b) and (c) Computed tomography of the thorax.
ses. Published by Elsevier Ltd. All rights reserved.
Table 1
Laboratory ﬁndings on day 16
Hematology Blood chemistry Serology/other
WBC 6.64  109/l Albumin 3.0 g/dl IgG 751 mg/dl
Myelo 3.0% LDH 216 IU/l Aspergillus GM 0.2 (normal, <0.5)
Meta 11.0% GOT 15 IU/l
Stab 6.0% GPT 8 IU/l KL-6 382 U/ml
Seg 59.0% ALP 191 IU/l b-D-glucan ND
Mono 17.0% Total bilirubin 0.3 mg/dl HIV-Ab ND
Lymph 3.0% BUN 7.5 mg/dl
RBC 3.03  1012/l Cr 0.89 mg/dl
Hemoglobin 8.6 g/dl Na 136 mEq/l
Hematocrit 26.6% K 4.0 mEq/l
Platelet count 299  109/l Cl 102 mEq/l
Reticulocytes 15.9% CRP 2.34 mg/dl
WBC, white blood cell count; Myelo, myelocytes; Meta, metamyelocytes; Stab, stab-form neutrophils; Seg, segmented neutrophils; RBC, red blood cell count; LDH, lactate
dehydrogenase; GOT, glutamic-oxaloacetic transaminase; GPT, glutamic-pyruvic transaminase; ALP, alkaline phosphatase; BUN, blood urea nitrogen; CRP, C-reactive
protein; aspergillus GM, aspergillus galactomannan; HIV-Ab, HIV antibody; ND, not detectable; Mono, monocytes; Lymph, lymphocytes.
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positive ﬁndings of PCR may lead to inappropriate treatment of
asymptomatic carriers of Pneumocystis, rather than clinically
signiﬁcant PCP, particularly in patients receiving corticosteroid
therapy or immunocompromised patients with lung disease.9
Recently, the utility of real-time PCR has been reported for
diagnosing PCP. This procedure is superior to conventional PCR in
terms of invasiveness and differentiating between asymptomatic
carriage and PCP.10,11
Drug-induced pneumonia can be excluded in this case, as all
drugs including rituximab and lenograstim were used repeatedly.
Although the extent to which clinical manifestations in this case
were associated with the nature of a cytokine storm occurring due
to the release of inﬂammatory mediators from recovering
neutrophils is unclear, PCP is considered the most likely diagnosis
in this case.
In conclusion, our report highlights an interesting case of PCP
with unusual presentation of serum markers in an HIV-negative
patient with diffuse large B-cell lymphoma. The PCR assay is
extremely useful for the diagnosis of PCP, particularly in early-
stage disease, due to the high sensitivity and speciﬁcity.
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